Gilead said that on February 1, 2024, at a Board meeting, the Board increased the size of the Board from nine directors to ten directors and elected Ted W. Love, M.D., to the Board, effective immediately after the close of the meeting.

1. 01

   Gilead said that on February 1, 2024, at a Board meeting, the Board increased the size of the Board from nine directors to ten directors and elected Ted W. Love, M.D., to the Board, effective immediately after the close of the meeting.

2. 02

   The company said Dr. Love will join the Audit Committee upon the conclusion of the 2024 Annual Meeting of Stockholders, subject to his re-election as a director at that meeting. He will receive compensation under the company's standard non-employee director program for the remainder of the 2023-2024 service period.

3. 03

   The company said there is no arrangement or understanding between Dr. Love and any other person under which he was selected as a director, and there are no related party transactions involving him that are reportable under Regulation S-K Item 404(a).

4. 04

   In its press release, the company said Dr. Love chairs the Board of the Biotechnology Innovation Organization and also serves on the boards of Royalty Pharma and Structure Therapeutics. He previously served as President and Chief Executive Officer of Global Blood Therapeutics.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.